| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910830255203321 |
|
|
Titolo |
Biologics, biosimilars, and biobetters : an introduction for pharmacists, physicians and other health practitioners / / edited by Iqbal Ramzan |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, New Jersey : , : Wiley, , 2021 |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-119-56468-9 |
1-119-56466-2 |
1-119-56469-7 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (xii, 302 pages) : illustrations (chiefly colour) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Biological products |
Biologicals |
Pharmaceutical biotechnology |
Biological Products |
Biosimilar Pharmaceuticals |
Biopharmaceutics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Innovator Biologics, Biosimilars and Biobetters : Terminology, Nomenclature and Definitions -- Approved Biologic Medicines and Biosimilars in Major Regulatory Jurisdictions -- Status of Biologic Drugs in Modern Therapeutics-Targeted Therapies vs Small Molecule Drugs -- Major Classes of Biotherapeutics -- Drug Targets for Biologics -- Pivotal Biology, Chemistry, Biochemistry and Biophysical Concepts of Biologics and Biosimilars -- Biosimilarity and Interchangeability of Biologic Drugs- General Principles, Biophysical Tests and Clinical Requirements to Demonstrate Biosimilarity -- Pharmacokinetics of Biologics -- Pharmacogenomics of Biologics -- International Regulatory Processes and Policies for Innovator Biologics, Biosimilars and Biobetters -- Pharmacovigilance of Innovator Biologics and Biosimilars -- Pharmacoeconomics of Biologic Medicines and Biosimilars / Gregory Reardon -- New Emerging Biotherapies : Cutting-Edge Research to Experimental Therapies -- Optimising Use of Biologic Medicines Using |
|
|
|
|
|
|
|
|
|
|
|
a Quality Use of Medicines Approach -- Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students -- A Checklist for Pharmacists on Biologics and Biosimilars - Tips to Enhance Patient-Centred Discussions. |
|
|
|
|
|
|
Sommario/riassunto |
|
"Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious successors (biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic and clinical utility. Pharmacists are the primary health care professionals who will provide advice to physicians, other health practitioners and patients on these drugs as governments and other third party payers attempt to contain their costs by introducing interchangeable products"-- |
|
|
|
|
|
|
|
| |